publication date: Feb. 21, 2020

Clinical Roundup

Updated CheckMate -025 results demonstrate superior OS, ORR for Opdivo in RCC

The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival  and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.

Bristol-Myers Squibb Co. sponsors Opdivo.

The data were presented Feb. 15 at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium in San Francisco.

With an extended minimum follow-up of 64 months, patients treated with Opdivo continue to demonstrate OS benefit with 26% of patients alive compared to 18% of patients treated with everolimus. The percentage of patients experiencing an objective response was 23% for Opdivo versus 4% for everolimus and the median duration of response for Opdivo was also maintained longer than for everolimus (18.2 months vs. 14 months, respectively). The overall safety profile was consistent with that observed in previously reported analyses from CheckMate -025 in patients with RCC. No new safety signals or drug-related deaths occurred with extended follow-up.

“Five-year survival results from the CheckMate -025 study, along with the ongoing response rates observed in the trial, highlight the potential for long-term survival and efficacy of nivolumab monotherapy for patients with previously-treated advanced RCC,” lead investigator Robert J. Motzer, Kidney Cancer Section Head at Memorial Sloan Kettering Cancer Center, said in a statement. “These data represent the longest follow-up for a PD-1 immune checkpoint inhibitor in this setting and underscore the potential increased survival rates nivolumab can deliver for patients with advanced RCC who have received prior antiangiogenic therapy.”

“The updated CheckMate -025 results support why Opdivo monotherapy … Continue reading Updated CheckMate -025 results demonstrate superior OS, ORR for Opdivo in RCC

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.